AbbVie and its subsidiary Allergan have had a long run of unchallenged success in the market with cosmetic and therapeutic treatment Botox. Now, the companies have extended their dominance to the ...
July 21 (Reuters) - A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie's (ABBV.N), opens new tab Allergan Inc $56 million after finding that Revance's anti-wrinkle medication ...
Allergan Aesthetics, the aesthetics unit of AbbVie Inc., was awarded $56 million in a patent infringement verdict against Nashville-based Revance Therapeutics. A Delaware federal jury on July 18 found ...
Botox generated $2.7B in global sales for 2024 Allergan Aesthetics scored a big legal patent infringement win tied to its blockbuster wrinkle-treatment Botox. A federal court in Delaware last month ...
On July 18, 2025, after a five-day trial, the jury in Allergan v. Revance Case No. 1:21-cv-01411 (D. Del.) entered a verdict finding claim 8 of Allergan’s U.S. Patent No. 7,354,740 (“the ’740 patent”) ...
A federal jury July 18 said Revance Therapeutics' skin medication infringed on patents for anti-wrinkle treatment Botox and owes AbbVie-owned Allergan $56 million. The lawsuit, filed by Ireland-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results